研究

M. Chiba, Y. Togashi, S. Tomida, H. Mizuuchi, Y. Nakamura, E. Banno, H. Hayashi, M. Terashima, M. A. De Velasco, K. Sakai, Y. Fujita, T. Mitsudomi and K. Nishio

MEK inhibitors against MET-amplified non-small cell lung cancer

Y. Kobayashi and T. Mitsudomi

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

T. Mitsudomi and Y. Kobayashi

Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?

H. Mizuuchi, K. Suda, I. Murakami, K. Sakai, K. Sato, Y. Kobayashi, M. Shimoji, M. Chiba, Y. Sesumi, K. Tomizawa, T. Takemoto, Y. Sekido, K. Nishio and T. Mitsudomi

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer

M. Shimoji, S. Shimizu, K. Sato, K. Suda, Y. Kobayashi, K. Tomizawa, T. Takemoto and T. Mitsudomi

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

K. Suda, I. Murakami, K. Sakai, K. Tomizawa, H. Mizuuchi, K. Sato, K. Nishio and T. Mitsudomi

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer

K. Suda, I. Murakami, H. Yu, K. Ellison, M. Shimoji, C. Genova, C. J. Rivard, T. Mitsudomi and F. R. Hirsch

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

K. Suda, C. J. Rivard, T. Mitsudomi and F. R. Hirsch

Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter

K. Tomizawa, M. Nishino, Y. Sesumi, Y. Kobayashi, K. Sato, M. Chiba, M. Shimoji, K. Suda, S. Shimizu, T. Sato, T. Takemoto and T. Mitsudomi

Prognostic impact of pleural lavage cytology in patients with primary lung cancer